124 related articles for article (PubMed ID: 11555574)
41. AQUA and FISH analysis of HER-2/neu expression and amplification in a small cell lung carcinoma tissue microarray.
Giltnane JM; Murren JR; Rimm DL; King BL
Histopathology; 2006 Aug; 49(2):161-9. PubMed ID: 16879393
[TBL] [Abstract][Full Text] [Related]
42. Expression of cyclooxygenase-2 (COX-2), receptors for estrogen (ER), and progesterone (PR), p53, ki67, and neu protein in endometrial cancer.
Ferrandina G; Ranelletti FO; Gallotta V; Martinelli E; Zannoni GF; Gessi M; Scambia G
Gynecol Oncol; 2005 Sep; 98(3):383-9. PubMed ID: 15979129
[TBL] [Abstract][Full Text] [Related]
43. Impact of Her-2 Neu overexpression on outcome of elderly women treated with wide local excision and breast irradiation for early stage breast cancer: an exploratory analysis.
Poltinnikov IM; Rudoler SB; Tymofyeyev Y; Kennedy J; Anne PR; Curran WJ
Am J Clin Oncol; 2006 Feb; 29(1):71-9. PubMed ID: 16462507
[TBL] [Abstract][Full Text] [Related]
44. Metastasis induced by overexpression of p185neu-T after orthotopic injection into a prostatic epithelial cell line (NbE).
Marengo SR; Sikes RA; Anezinis P; Chang SM; Chung LW
Mol Carcinog; 1997 Jul; 19(3):165-75. PubMed ID: 9254883
[TBL] [Abstract][Full Text] [Related]
45. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
[TBL] [Abstract][Full Text] [Related]
46. Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival.
Cheville JC; Tindall D; Boelter C; Jenkins R; Lohse CM; Pankratz VS; Sebo TJ; Davis B; Blute ML
Cancer; 2002 Sep; 95(5):1028-36. PubMed ID: 12209687
[TBL] [Abstract][Full Text] [Related]
47. Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer.
Ferrandina G; Ranelletti FO; Lauriola L; Fanfani F; Legge F; Mottolese M; Nicotra MR; Natali PG; Zakut VH; Scambia G
Gynecol Oncol; 2002 May; 85(2):305-10. PubMed ID: 11972392
[TBL] [Abstract][Full Text] [Related]
48. Clinical relevance of HER-2/neu expression in germ-cell testicular tumors.
Mándoky L; Géczi L; Bodrogi I; Tóth J; Csuka O; Kásler M; Bak M
Anticancer Res; 2004; 24(4):2219-24. PubMed ID: 15330164
[TBL] [Abstract][Full Text] [Related]
49. Comparison of serum HER2/neu with immunohistochemical HER2/neu expression for the prediction of biochemical progression in metastatic prostate cancer.
Tambo M; Higashihara E; Terado Y; Nutahara K; Okegawa T
Int J Urol; 2009 Apr; 16(4):369-74. PubMed ID: 19207111
[TBL] [Abstract][Full Text] [Related]
50. HER-2/neu and p53 overexpression as biomarkers of breast carcinoma in women age 30 years and younger.
Maru D; Middleton LP; Wang S; Valero V; Sahin A
Cancer; 2005 Mar; 103(5):900-5. PubMed ID: 15643600
[TBL] [Abstract][Full Text] [Related]
51. Differences in the pathologic and molecular features of intraductal breast carcinoma between younger and older women.
Rodrigues NA; Dillon D; Carter D; Parisot N; Haffty BG
Cancer; 2003 Mar; 97(6):1393-403. PubMed ID: 12627502
[TBL] [Abstract][Full Text] [Related]
52. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.
Zhou M; Hayasaka S; Taylor JM; Shah R; Proverbs-Singh T; Manley S; Rubin MA
J Urol; 2001 Dec; 166(6):2193-7. PubMed ID: 11696734
[TBL] [Abstract][Full Text] [Related]
53. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
[TBL] [Abstract][Full Text] [Related]
54. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase.
Igawa T; Lin FF; Rao P; Lin MF
Prostate; 2003 Jun; 55(4):247-58. PubMed ID: 12712404
[TBL] [Abstract][Full Text] [Related]
55. Her-2-neu expression and progression toward androgen independence in human prostate cancer.
Signoretti S; Montironi R; Manola J; Altimari A; Tam C; Bubley G; Balk S; Thomas G; Kaplan I; Hlatky L; Hahnfeldt P; Kantoff P; Loda M
J Natl Cancer Inst; 2000 Dec; 92(23):1918-25. PubMed ID: 11106683
[TBL] [Abstract][Full Text] [Related]
56. Overexpression of her-2/neu in human prostate cancer and benign hyperplasia.
Gu K; Mes-Masson AM; Gauthier J; Saad F
Cancer Lett; 1996 Feb; 99(2):185-9. PubMed ID: 8616823
[TBL] [Abstract][Full Text] [Related]
57. Her-2/neu expression in prostate cancer: high level of expression associated with exposure to hormone therapy and androgen independent disease.
Shi Y; Brands FH; Chatterjee S; Feng AC; Groshen S; Schewe J; Lieskovsky G; Cote RJ
J Urol; 2001 Oct; 166(4):1514-9. PubMed ID: 11547123
[TBL] [Abstract][Full Text] [Related]
58. Overexpression of HER-2/neu in patients with prostatic adenocarcinoma.
Zahir ST; Tafti HF; Rahmani K
Asian Pac J Cancer Prev; 2014; 15(15):6425-8. PubMed ID: 25124637
[TBL] [Abstract][Full Text] [Related]
59. Validation of a quantitative flow cytometer assay for monitoring HER-2/neu expression level in cell-based cancer immunotherapy products.
Randlev B; Huang LC; Watatsu M; Marcus M; Lin A; Shih SJ
Biologicals; 2010 Mar; 38(2):249-59. PubMed ID: 20080049
[TBL] [Abstract][Full Text] [Related]
60. Overexpression of p185erbB2/neu in the NbE prostatic epithelial cell line increases cellular spreading and the expression of integrin alpha6beta1.
Vafa A; Zhang Y; Sikes RA; Marengo SR
Int J Oncol; 1998 Dec; 13(6):1191-7. PubMed ID: 9824630
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
